Tata Capital, Maruti Suzuki India, Urban Company, NTPC, Bank of Baroda and Cipla are among over 300 companies scheduled to ...
The company is banking on key new launches, including weight loss drug Semaglutide and biosimilar Abatacept to drive growth ...
From generics glory to a billion-dollar dream of discovery, how Dr. Anji Reddy’s audacious vision reshaped Indian pharma—and ...
Markets end six-day rally as profit booking and trade policy concerns weigh on investor sentiment, with mixed sector ...
Why is the Supreme Court’s directive to notify a new Saranda wildlife sanctuary important for your UPSC exam? What ...
() -Indian generic drugmaker Dr Reddy's Laboratories reported second-quarter profit below estimates on Friday, hurt by higher costs and stiff competition for the generic version of cancer drug ...
The Stock Market on Friday snapped a six-day winning streak and dragged Nifty near 25,700 intraday. The development comes amid selling across the sectors, barring metal and telecom names. At close, ...
The cornerstone of this strategic offensive is the drug Tirzepatide, a compound already achieving blockbuster status in other global markets for treating Type 2 diabetes and obesity. Under the brand ...
Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...
Cipla, HUL, Adani Ports, Max Healthcare, UltraTech Cement were among top losers on the Nifty, while gainers were Hindalco, ...
Asianet Newsable on MSN
Cipla Shares Fall To Biggest Intra-day Lows In Six Months Despite Eli Lilly Deal For Diabetes Drug
Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India Tirzepatide is used to manage type 2 ...
On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback